18th Annual Conference of the British HIV Association (BHIVA)



Dr Lucy Dorrell

University of Oxford

18-20 April 2012, The International Convention Centre, Birmingham

The antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ cell decline in HIV-1 infection

Hongbing Yang, Hao Wu, Gemma Hancock, Genevieve Clutton, Nellia Sande, Xiaoning Xu, Huiping Yan, Xiaojie Huang, Brian Angus, Kristin Kuldanek, Sarah Fidler, Thomas N. Denny, Jacqueline Birks, Andrew McMichael,

Lucy Dorrell

University of Oxford

Background

- * HIV-specific CD8+ T cell responses control acute viraemia but fail to clear or control infection
- * Superior functional capacity of HIVspecific CD8+ T cells from HIV controllers / long-term nonprogressors
- * Cause or consequence of long-term virus control?
- Laboratory assays do not adequately reflect immune recognition of HIV in vivo

CD8+ T cell antiviral inhibitory activity: an immune correlate of HIV control?



 Potent inhibition of HIV replication by ex vivo CD8+ T cells

(Saez-Cirion et al., 2007, Freel et al., 2010)

- * Unique to HIV controllers?
- * A determinant of the rate of disease progression in viraemic individuals?

Aims

- To investigate the relationship between CD8+ T cell antiviral activity and HIV progression in chronic infection
- To determine whether CD8+ T cell antiviral activity in early HIV infection can predict HIV progression



Reduction in viral growth by CD8+ T cell is expressed as % inhibition

(% infected CD4+ cells (p24⁺⁾ in CD4/CD8 co-culture)

% infected cells in CD4+ cells alone

CD8+ T cell antiviral activity is expressed on a continuum in chronic HIV infection

- * 30 patients with chronic HIV infection, ART-naïve, asymptomatic
- CD4 counts > 350 cells/μl
- * 20 males, 10 females
- Median age 34 yrs
- Median diagnosed infection: 3 years
- Protective HLA class I allele 20%



CD8+ T cell antiviral suppressive activity in chronic HIV infection is strongly associated with the rate of CD4+ cell decline

CD4 slopes derived from median 4.5 years' follow-up

Linear mixed models to investigate interaction between CD4 slope and CD8+ T cell antiviral activity (% inhibition)



Is potent CD8+ T cell antiviral activity the cause or consequence of HIV disease control?

- Prospective study in recently infected patients with known date of HIV-1 acquisition – Beijing PRIMO cohort
- CD8+ T cell antiviral activity measured at a single timepoint in early infection
- Examined predictive value of % inhibition for the rate of CD4 decline over first 3 years of infection

Prospective analysis of 20 patients with recent HIV infection

- * 20 MSM, ART-naïve, asymptomatic
- * CD4 counts > 350 cells/μl
- * Median age 28 yrs
- CD8+ T cell antiviral activity measured at single time-point at 3 CD8+/CD4+ cell ratios
- Duration of infection: median 198 days
- * Follow-up: median 895 days
- Protective HLA class I allele*: n = 6 (30%)



Linear mixed models analysis

- CD8+ T cell antiviral activity was a strong predictor of the rate of CD4+ cell decline at all CD8+/CD4+ cell ratios tested (p < 0.0001)
- Explained up to 73% of inter-individual variation in CD4 slope

Potent CD8+ T cell antiviral activity is associated with longer survival with CD4 > 350 cells/ μ l



Summary

- * Assay enables measurement of 'total' HIV-specific CD8+ T cell response
- * The capacity of CD8+ T cells to inhibit HIV replication in vitro is:
 - highly predictive of the rate of CD4+ cell decline in the first 3 years of infection
 - explains majority of inter-individual variation in CD4 slope
 - inversely correlated with viral load set-point

Implications

- Assessment of CD8+ T cell function could have prognostic value in patients with CD4 counts above current thresholds for ART-initiation
- Potential as a benchmark of effective immunity in the clinical evaluation of HIV vaccine candidates

Acknowledgements

University of Oxford

Weatherall Institute of Molecular Medicine Hongbing Yang Gemma Hancock Genevieve Clutton Lisette Yorke Adam Ritchie Nilu Goonetilleke Andrew McMichael Centre for Statistics in Medicine, Jacqueline Birks

Oxford University Hospitals

Nellia Sande Brian Angus

Beijing YouAn Hospital

Xiaoning Xu Hao Wu Huiping Yan Xiaojie Huang

Imperial College London Sarah Fidler Kristin Kuldanek

Volunteers

Oxford Biomedical Research Centre





Oxford Radcliffe Hospitals NHS NHS Trust



National Institute for Health Research